Evidence map›Paper›PMID 41755642›Full record

ArticleNucleic acids research2026

A de novo H3.2K9me2 deposition pathway establishes heterochromatin for suppressing transposon mobilization during fly somatic development.

Yi Ni Luo, Yazi Deng, Yu Liang, Wei Wu, Wei Wu, Lu Wang

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yi Ni LuoState Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
Yazi DengState Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
Yu LiangKey Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
Wei WuState Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
Wei WuKey Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.ORCID 0000-0001-5164-2765
Lu WangState Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.ORCID 0000-0003-2356-6245

Funding

Chinese Academy of Sciences 318GJHZ2023004MIChinese Academy of Sciences XDB0570000Chinese Academy of Sciences XDB0990000General Program of NSFC 32 270 600General Program of NSFC 32 370 575National Key Research and Development Project 2021YFA0805805National Key Research and Development Project 2022YFA1103900Ruisi Research Center for Life ScienceScience and Technology Commission of Shanghai Municipality 22ZR1468800Shanghai Academy of Natural SciencesShanghai Municipal Science and Technology Major ProjectShanghai Pujiang Program 21PJ1414000Shanghai Rising-Star Program 24QA2710100
6 · The paper itself

Abstract

Histone variants along with their associated chaperones have been considered as one of the major complexes to provide versatility in organizing chromatin structure. Post-translational modifications (PTMs) of H3 variants serve as very important factors in promoting heterochromatin assembly, protecting telomere stability, and suppressing transposon activity. However, the precise mechanism by which specific PTMs on H3 variants suppress transposons remains elusive. Here, by monitoring retrotransposon mobilization during Drosophila hindgut development, we identified the DNA synthesis-coupled (DSC) H3.2K9me2 deposition pathway as a pivotal mechanism for transposon suppression. Depleting the factors in the DSC H3.2 complex, but not in the DNA synthesis-independent (DSI) H3.3 chaperone pathway, unleashed massive retrotransposon activation. DSC chaperones specifically establish dimethylation at the H3.2K9 site in heterochromatic regions by directly interacting with and recruiting the histone methyltransferase, G9a. Intriguingly, the cross-talk between DSC H3.2K9me2 and DSI H3.3K9me3 in heterochromatin is dynamically regulated and properly balanced. Although DSI H3.3K9me3 could efficiently be incorporated into transposon loci when the DSC H3.2K9me2 deposition pathway was disrupted, H3.3K9me3 alone was insufficient to establish functional heterochromatin required for transposon silencing during development. Altogether, our discoveries provide a framework to understand how cells employ specific histone variant modifications to construct and maintain heterochromatin, thereby ensuring transposon repression and safeguarding genome integrity.

Indexed as

DNA Transposable ElementsDrosophila melanogasterDrosophila ProteinsHeterochromatinHistonesRetroelementsAnimalsHistone-Lysine N-MethyltransferaseMethylationProtein Processing, Post-TranslationalDNA Transposable ElementsDrosophila ProteinsHeterochromatinHistone-Lysine N-MethyltransferaseHistonesRetroelements

Identifiers

PMID41755642
PMCPMC12956338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.